TRexBio raises $84M to take in-house immune program into the clinic

Bay Area immunology biotech TRexBio has raised a $84 million Series B to start clinical studies of a potential treatment for atopic dermatitis and ulcerative colitis. The biotech’s lead candidate, unveiled last year, is a ...